[Sequence Contract Analysis] Peace of mind even with 1 sample! The price includes data analysis. For model organisms, a short turnaround of 3 to 4 weeks is also possible.
RNA-seq is one of the NGS sequencing contract analysis methods that comprehensively analyzes gene expression (transcriptome). It can accommodate various species and analyze the expression levels of genes and transcripts as well as splicing patterns. ■ Comprehensive analysis of the transcriptome ■ Analysis of expression levels of genes and transcripts and splicing patterns ■ Identification of novel transcripts ■ Proven results in various species, including model organisms. (e.g., humans, mice, plants, fish, frogs, yeast, bacteria, etc.) Our company also offers a unique technology contract analysis service called CAGE-seq. ■ PCR-free, providing excellent quantitativeness, with detection sensitivity approximately 7 times higher than RNA-seq analysis ■ Strong in detecting RNA transcription start sites ■ Applicable to eukaryotic organisms with genomic information, including model organisms ■ There are examples of usage where the differentiation of transcription start sites in cancer and diseases has been utilized for biomarker candidate exploration. * We are currently offering a booklet that clearly introduces the principles and benefits. It explains the differences between RNA-seq and CAGE-seq, as well as their technologies and prices in an easy-to-understand FAQ format.
Inquire About This Product
basic information
【Contracted Service Details】 ■ Total RNA Quality Inspection ■ Library Preparation ■ Sequencing ■ Base Calling ■ Data Analysis *For more details, please refer to the catalog or feel free to contact us.
Price range
P2
Delivery Time
Applications/Examples of results
For more details, please refer to the catalog or feel free to contact us.
catalog(8)
Download All CatalogsCompany information
Danaform Inc. is a company established in 1998, based on the RIKEN Venture System of the National Research and Development Agency RIKEN, with Yoshihide Hayasaki from RIKEN (who has been the representative director of Danaform Inc. since 2021) at its core. The company is actively engaged in gene analysis and genetic testing, focusing on technologies co-developed by Danaform and RIKEN, including contract analysis using next-generation sequencers such as CAGE-seq and RNA-seq, the sale of fluorescent reagents Eprobe capable of SNP detection, and the sale of various clones, boasting a significant inventory. Moving forward, we aim to refine our proprietary technologies and strive for higher quality research and manufacturing as experts in the field of genetics, with the hope of contributing to people's health.